Redwood Pharma to Attend Bio-Europe 2017, Nov. 6 - 8 in Berlin for Partnering Discussions
Redwood Pharma will be attending Bio-Europe 2017 in Berlin, Nov. 6 – 8 to meet and continue discussions with potential pharmaceutical partners regarding co-development and licensing of RP101, the Company’s therapy to treat chronic dry eye disease in postmenopausal women and the IntelliGel drug delivery platform.RP101 is the Company’s lead program for the development of a novel treatment of chronic dry eye disease in postmenopausal women. The active substance is an endogenous small molecule already proven safe and effective in two Phase II clinical trials conducted in the US. The active